ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO180

Senolytics, Dasatinib Plus Quercetin, Improve Kidney Function and Reduce Inflammation in Murine Diabetic Kidney Disease

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic

Authors

  • Bian, Xiaohui, Mayo Clinic in Florida, Jacksonville, Florida, United States
  • Snow, Zachary Kayne, Mayo Clinic in Florida, Jacksonville, Florida, United States
  • Smith, Anastasia L., Mayo Clinic in Florida, Jacksonville, Florida, United States
  • Skaff, Caroline Janet, Mayo Clinic in Florida, Jacksonville, Florida, United States
  • Elhusseiny, Khaled Mosaad, Mayo Clinic in Florida, Jacksonville, Florida, United States
  • Zhu, Yi, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Tchkonia, Tamara, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Kim, Seo Rin, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Kirkland, James L., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Lerman, Lilach O., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Hickson, LaTonya J., Mayo Clinic in Florida, Jacksonville, Florida, United States

Group or Team Name

  • Mayo Translational and Regenerative Nephrology Research Laboratory
Background

Senolytic agents, dasatinib plus quercetin (D+Q), reduced systemic inflammation, macrophage infiltration, and senescent cell burden in adipose tissue in our pilot study of human participants with diabetic kidney disease (DKD). We hypothesized that D+Q would attenuate kidney injury and inflammation in a murine model of DKD.

Methods

Twelve-week-old male C57BL/6 mice were injected with 50 mg/kg/d STZ i.p. for 5 (+3) consecutive days (Figure). Mice with fasting glucose >250 mg/dL at day 100 were randomized to either D+Q (5 and 50 mg/kg, respectively) or vehicle gavage daily for 5 days and euthanized 20 days later. Kidney injury (Mac-2, KIM-1), inflammation (MCP-1, IL-6, IL-1β, TNFα), profibrotic markers (TGFβ1, fibronectin), cellular senescence (p16), and geroprotective factors (α-Klotho, Sirt-1) were examined by qPCR, and kidney function by serum creatinine. In vitro, we assessed the response to D+Q in renal tubular epithelial cells (HK2) injured by high glucose and TGF-β1.

Results

Oral D+Q improved kidney function and decreased kidney injury, profibrotic factors, and senescence marker p16 vs. vehicle-treated mice. In addition, pro-inflammatory (senescence-associated secretory proteins) kidney makers were reduced following D+Q. Finally, both α-Klotho and Sirt-1 increased in DKD tissue in vivo and HK2 cells in vitro after D+Q.

Conclusion

A “hit and run” treatment with D+Q can attenuate murine DKD injury by altering the inflammatory landscape, reducing senescent cell abundance, and restoring geroprotective factors. D+Q might represent a novel therapeutic strategy in DKD.

Funding

  • NIDDK Support